ACAD
36.045
-2.315
-6.035%
AEMD
0.196
-0.01
-4.6341%
APRI
1.62
+0.01
+0.62%
ARNA
4.22
-0.27
-6.01%
ATEC
1.41
0.00
0.00%
CNAT
6.35
-0.31
-4.65%
CRXM
0.415
+0.061
+17.397%
CYTX
0.915
-0.07
-7.107%
DXCM
67.56
-1.87
-2.69%
GNMK
10.35
-0.34
-3.18%
HALO
15.78
-1.08
-6.41%
ILMN
183.71
-5.88
-3.10%
INNV
0.145
0.00
0.00%
INO
10.055
-0.295
-2.850%
ISCO
0.074
-0.001
-0.6757%
ISIS
62.02
-4.35
-6.55%
LGND
87.3
-2.45
-2.73%
LPTN
2.23
0.00
0.00%
MBVX
3.17
-0.19
-5.65%
MEIP
2.07
-0.09
-4.17%
MNOV
3.76
-0.33
-8.07%
MRTX
26.98
-0.89
-3.19%
MSTX
0.476
-0.014
-2.857%
NBIX
39.5
-3.87
-8.92%
NUVA
43.36
-0.63
-1.43%
ONCS
0.291
+0.023
+8.582%
ONVO
4.87
-0.32
-6.17%
OREX
6.95
-0.41
-5.57%
OTIC
28.58
-3.22
-10.13%
QDEL
23.41
+0.03
+0.13%
RCPT
156.22
-13.66
-8.04%
RGLS
14.59
-2.9
-16.58%
RMD
64.55
-1.15
-1.75%
SCIE
0.019
-0.007
-27.95367%
SPHS
0.75
-0.05
-6.24%
SRNE
9.36
-1.16
-11.03%
TROV
8.27
-0.53
-6.02%
VICL
0.96
-0.05
-4.48%
VOLC
17.99
0.00
0.00%
ZGNX
1.41
-0.13
-8.44%
ACAD
36.045
-2.315
-6.035%
AEMD
0.196
-0.01
-4.6341%
APRI
1.62
+0.01
+0.62%
ARNA
4.22
-0.27
-6.01%
ATEC
1.41
0.00
0.00%
CNAT
6.35
-0.31
-4.65%
CRXM
0.415
+0.061
+17.397%
CYTX
0.915
-0.07
-7.107%
DXCM
67.56
-1.87
-2.69%
GNMK
10.35
-0.34
-3.18%
HALO
15.78
-1.08
-6.41%
ILMN
183.71
-5.88
-3.10%
INNV
0.145
0.00
0.00%
INO
10.055
-0.295
-2.850%
ISCO
0.074
-0.001
-0.6757%
ISIS
62.02
-4.35
-6.55%
LGND
87.3
-2.45
-2.73%
LPTN
2.23
0.00
0.00%
MBVX
3.17
-0.19
-5.65%
MEIP
2.07
-0.09
-4.17%
MNOV
3.76
-0.33
-8.07%
MRTX
26.98
-0.89
-3.19%
MSTX
0.476
-0.014
-2.857%
NBIX
39.5
-3.87
-8.92%
NUVA
43.36
-0.63
-1.43%
ONCS
0.291
+0.023
+8.582%
ONVO
4.87
-0.32
-6.17%
OREX
6.95
-0.41
-5.57%
OTIC
28.58
-3.22
-10.13%
QDEL
23.41
+0.03
+0.13%
RCPT
156.22
-13.66
-8.04%
RGLS
14.59
-2.9
-16.58%
RMD
64.55
-1.15
-1.75%
SCIE
0.019
-0.007
-27.95367%
SPHS
0.75
-0.05
-6.24%
SRNE
9.36
-1.16
-11.03%
TROV
8.27
-0.53
-6.02%
VICL
0.96
-0.05
-4.48%
VOLC
17.99
0.00
0.00%
ZGNX
1.41
-0.13
-8.44%
Home » Archive by Category

Xconomy

In Move That Spells Relief, Zogenix Sells Painkiller to Pernix

March 10, 2015 – 6:50 pm

Zohydro was supposed to be a new kind of painkiller, but it gave Zogenix CEO Roger Hawley a headache that lasted more than a year. Now perhaps he can rest a little easier. After introducing Zohydro…

[[Click headline to continue reading.]]

In Move That Spells Relief, Zogenix Sells Painkiller to Pernix

March 10, 2015 – 6:50 pm

Zohydro was supposed to be a new kind of painkiller, but it gave Zogenix CEO Roger Hawley a headache that lasted more than a year. Now perhaps he can rest a little easier. After introducing Zohydro…

[[Click headline to continue reading.]]

Companion Diagnostic Specialist AltheaDx Withdraws IPO

March 10, 2015 – 8:20 am

San Diego’s AltheaDx, which offers a series of molecular diagnostic tests that enable doctors to identify the optimal drugs for treating patients, yesterday withdrew its plans for an initial public…

[[Click headline to continue reading.]]

NIH Director Hails “Stunning Case” as Example of Genomic Revolution

March 6, 2015 – 7:37 am

A pregnant mom who got a non-invasive prenatal test because she knew at age 40 that her baby was a higher risk for Down syndrome has become a case study in the potential power of precision medicine….

[[Click headline to continue reading.]]

NIH Director Hails “Stunning Case” as Example of Genomic Revolution

March 6, 2015 – 7:37 am

A pregnant mom who got a non-invasive prenatal test because she knew at age 40 that her baby was a higher risk for Down syndrome has become a case study in the potential power of precision medicine….

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Pharmacyclics, Gates, Ikaria & More

March 5, 2015 – 3:01 pm

[Corrected 3/9/15, 11:46 pm. See below.] What a week for West Coast news, topped off by AbbVie’s surprise $21 billion grab of Pharmacyclics. It’s the ninth-largest biopharma acquisition…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Pharmacyclics, Gates, Ikaria & More

March 5, 2015 – 3:01 pm

[Corrected 3/9/15, 11:46 pm. See below.] What a week for West Coast news, topped off by AbbVie’s surprise $21 billion grab of Pharmacyclics. It’s the ninth-largest biopharma acquisition…

[[Click headline to continue reading.]]

With Narrowed Focus, Elcelyx Prepares for Diabetes Drug Trial

March 5, 2015 – 6:30 am

For San Diego’s Elcelyx Therapeutics, 2014 may someday be remembered as “the year of heavy lifting.” Since the fall of 2013, when Elcelyx spun out NaZura BioHealth as a sister company with the same…

[[Click headline to continue reading.]]

With Narrowed Focus, Elcelyx Prepares for Diabetes Drug Trial

March 5, 2015 – 6:30 am

For San Diego’s Elcelyx Therapeutics, 2014 may someday be remembered as “the year of heavy lifting.” Since the fall of 2013, when Elcelyx spun out NaZura BioHealth as a sister company with the same…

[[Click headline to continue reading.]]

“Voice for Everyone”—Life-Sci Women Talk Venture, Pharma Gender Gap

March 4, 2015 – 3:55 pm

By the numbers, the rare-disease drug developer Raptor Pharmaceutical (NASDAQ: RPTP) recently upped its chances of better market performance. That’s because biopharma veteran Julie Anne Smith…

[[Click headline to continue reading.]]